Participate in Both J.P. Morgan Health Conference 2020 and Biotech Showcase in
San Francisco, Ca, USA
Inc. (KOSDAQ: 208340) announced today that Dr. Jin-San Yoo, the CEO of the
company and other delegates will attend the 38th
annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel on January 12-16 and
Biotech Showcase at the Hilton San Francisco Union Square on January 13-15,
2020. During the week of conference, PharmAbcine will evaluate and discuss strategic
partnership with a number of global pharmaceutical companies, global investment
bankers, biopharma and innovative biotech companies.
Jin-San Yoo will present company’s clinical and pre-clinical developmental
pipeline at Biotech Showcase. The details of the presentation are as
Date: January 14, 2020
Time: 3:00 PM PST
Track: Yosemite C (Ballroom Level)
Venue: Hilton San Francisco Union Square.
the annual J.P. Morgan Health Conference and Biotech Showcase are the largest
and most informative annual healthcare symposiums in the industry, bringing
together industry leaders, emerging fast growing biopharmaceutical and life
sciences companies, and members of investment community.
more information about J.P. Morgan Health Conference and Biotech Showcase,
Ÿ J.P. Morgan
Health Conference: https://jpmhealthconference.org/
About PharmAbcine Inc.
is a clinical-stage biotech company, listed in KOSDAQ stock market (208340),
focusing on the development of fully human antibody (mAb) therapeutics,
especially reputed for leading the development of next-generation
multi-specifics. This multi-specific antibody technology can be achieved
through our in-house novel technology development, namely DIG-Body, PIG-Body
and TIG-Body. Using innovative discovery technology and excellent human
resources, we provide a number of superlative immunotherapeutics for
indications in immuno-oncology, immunology and ophthalmology.
HuPhage library and innovative selection system are priceless proprietary
assets. Additionally, our well-established 3G expression system ultimately
helped concrete our stupendous reputation in the field of biopharma industry by
allowing us to achieve the reinforcement and reproducibility of high levels of
antibody production. On the basis of our highly maintained, advanced technical
systems, we are pleased to provide high quality antibody generation services.
Moreover, our high standards antibodies have allowed us to be actively involved
in co-development with our partners and we are willing to expand co-development
opportunities to other potential partners.
the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has more than 300
patients-derived cancer stem cell libraries and an animal model system for
evaluating internal pipeline development.
TTAC-0001(olinvacimab): It is an
anti-VEGFR2 fully human IgG with unique cross reactivity between mouse and
human and has completed a Phase IIa recurrent glioblastoma multiforme (rGBM)
trial in Australia in August 2017. It is currently in a phase 2 clinical trial
in Australia and USA for bevacizumab-refractory rGBM patients. Being an
anti-angiogenesis agent that has shown good safety profile and efficacy in rGBM
patients, TTAC-0001 is a good candidate to develop combination therapy with
other cancer therapeutics and we are currently running two phase 1b clinical
trials with pembrolizumab in rGBM and mTNBC patients.
PMC-001, PMC-002 &
They are a series of next generation bispecific antibody neutralizing both VEGFR2
and Ang2-TIE2 pathways. It has been shown to be more efficacious than
monotherapy using bevacizumab or olinvacimab alone in preliminary studies.
PMC-122: A novel
bispecific antibody neutralizing both PD1-PDL1 and SIRPα-CD47 pathways. We
developed a strategy to maximize inhibiting the pathways in TME (tumour
microenvironment) while minimizing the effects on RBC (both tumour cells and
RBCs express CD47).
PMC-201: It is a
next generation bispecific antibody neutralizing both VEGFR2 and Notch-DLL4.
DLL4/Notch-1 pathway is involved in maintaining CSC’s (cancer stem cells) and
thus, targeting both VEGFR2 and DLL4 can effectively block malignant
proliferation, metastasis, as well as tumor recurrence caused by DLL4 positive
CSCs. In order to minimize any side
effects associated with targeting DLL4, PMC-201 was built upon TTAC-0001 IgG
backbone that is proven to be safe in cancer patients and it is designed to specifically
bind to the DLL4 expressed on tumor cells. We confirmed PMC-201 has strong
anti-tumor activities in tumor-bearing mice.
PMC-309: It is a
fully human antibody targeting VISTA that is highly expressed on the surface of
MDSCs (myeloid-derived suppressor cells) and TAMs (tumour-associated
macrophages) present in the TME. We have multiple classes of anti-VISTA
antibodies that are being characterized in different environment.
PMC-401S: It is a
novel monospecific anti-Ang2 in ScFv (single chain variable fragment) format. By
blocking Ang2-Tie2 pathway without affecting Ang1 binging to Tie2, it functions
as an active vessel stabilizer. It showed great efficacy in age-related macular
degeneration (AMD) and diabetic retinopathy (DR) animal models.
PMC-402: It is a
Tie2 targeting antibody. Upon binding to the Tie2 as an agonist, it stabilizes
leaky tumor vessels into functional ones and we are exploring a combination
therapy of PMC-402 with other cancer therapeutics. It is also being developed
to treat posterior segment eye diseases such as AMD and DR in ophthalmology.
neutralizes EGFR variant III (EGFRvIII). With its internalization property, it
can be incorporated to develop ADC (antibody-drug conjugate), CAR-T (chimeric
antigen receptor T cell) and CAR-NK (chimeric antigen receptor NK cell).
biosimilar cell line with higher titer than originator
biosimilar cell line with higher titer than originator
all the pipelines listed, we are open for out-licensing and co-development of
information about PharmAbcine can be found on our website at
please visit the biospace website: https://www.biospace.com/article/pharmabcine-to-participate-in-both-j-p-morgan-health-conference-2020-and-biotech-showcase-in-san-francisco-ca-usa/